11:30 AM EDT, 08/08/2025 (MT Newswires) -- Gilead Sciences' ( GILD ) Q2 results exceeded analyst expectations driven by strength in its HIV drug segment, and the company is forecast to generate 3% growth in annual HIV product sales in 2025, Truist Securities said in a report Friday.

While the recent launch of the new HIV preventative injection Yeztugo was too recent to impact Q2 numbers, analysts said they are optimistic about the drug's future, adding that they continue to believe the biopharmaceutical company "has the best-in-class, unparalleled HIV business in the sector."

The company's oncology segment also showed strength, with its drug Trodelvy returning to growth with a 14% increase in sales compared to the same quarter last year, the note said.

Yeztugo is in its initial stages but the early script data is "trending in the right direction," Truist said in a separate report Friday. Despite limited prescription data, a broader uptake is expected once J-code reimbursement takes effect in October, the analysts said.

Truist upgraded the stock to buy from hold and raised its price target to $127 from $108.

Shares of the company were up more than 8% in recent Friday trading.

Price: 119.95, Change: +9.66, Percent Change: +8.76